Authorization

Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwritersa?? Option to Purchase Additional American Depositary Shares

PHILADELPHIA, Pa. and OXFORD, United Kingdom, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (a??Adaptimmunea??) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that the underwriters of its previously announced public offering of 21,000,000 American Depositary Shares (a??ADSsa??), which initially closed on January 24, 2020, have exercised in full their option to purchase an additional 3,150,000 of its ADSs at a price to the public of $4.00 per ADS, raising additional net proceeds of approximately $11.7 million, after deducting underwriting discounts and commissions and estimated offering expenses. The option exercise closed on February 7, 2020.A A 
After giving effect to the option exercise, Adaptimmune sold a total of 24,150,000 ADSs in connection with the offering, generating net proceeds of approximately $89.8 million, after deducting the underwriting discount and other offering expenses payable by Adaptimmune. Adaptimmune intends to use the net proceeds from this offering to advance the development of its immunotherapies into and through clinical trials as well as for other general corporate purposes.Cowen acted as sole book-running manager for the offering and Roth Capital Partners acted as co-manager for the offering.A shelf registration statement on FormA S-3 relating to the public offering of the ADSs described above was declared effective by the Securities and Exchange Commission (a??SECa??) on September 10, 2019. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SECa??s web site at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to these securities may also be obtained by sending a request to: Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926.This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Октябрь 2021    »
ПнВтСрЧтПтСбВс
 123
45678910
11121314151617
18192021222324
25262728293031